Clyde Green, MD
Family Medicine · Macon, GANPI 1417178187
Payments from drug & device makers
Across 816 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$809
- Lilly USA, LLC$747
- Amgen$700
- Sumitomo Pharma America, Inc.$690
- plus $9K from 54 others
What the payments were for
- Food & beverage$14,96899%
- Education$1841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$233
- IBSRELA$135
- Repatha$125
- FASENRA$125
- AIMOVIG$125
- Prolastin-C$124
- CAPLYTA$123
- VRAYLAR$121
- MazorX - Renaissance$103
How this compares
$15,152 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $116,666 |
| AptiomEslicarbazepine Acetate | 164 | $108,801 |
| TrulicityDulaglutide | 113 | $104,366 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 24 | $99,910 |
| EliquisApixaban | 292 | $95,239 |
| Risperdal ConstaRisperidone Microspheres | 81 | $89,343 |
| FarxigaDapagliflozin Propanediol | 170 | $81,505 |
| JardianceEmpagliflozin | 99 | $79,112 |
| RexultiBrexpiprazole | 94 | $71,673 |
| Invega SustennaPaliperidone Palmitate | 19 | $55,381 |
| EntrestoSacubitril/Valsartan | 143 | $51,989 |
| TradjentaLinagliptin | 123 | $44,855 |
| MyrbetriqMirabegron | 99 | $44,440 |
| KerendiaFinerenone | 36 | $40,321 |
| NuedextaDextromethorphan Hbr/Quinidine | 73 | $36,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal Consta, Invega Sustenna, Prezcobix, Xarelto | $170 | $194,681213 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $343 | $136,609235 claims |
| Novo NordiskOzempic, Fiasp | $809 | $130,592125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $747 | $127,461135 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $426 | $108,801164 claims |
| PfizerEliquis | $604 | $95,239292 claims |
| AstraZenecaFarxiga | $1,609 | $81,505170 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $475 | $71,67394 claims |
| MerckJanumet Xr, Janumet, Belsomra, Januvia | $233 | $66,752107 claims |
| AbbVieLinzess, Vraylar | $1,430 | $55,58670 claims |
| NovartisEntresto | $190 | $51,989143 claims |
| Astellas Pharma US IncMyrbetriq | $464 | $44,44099 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Macon
- Frederick BurtonMacon$66K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.